all report title image
  • Published On : Mar 2022
  • Code : CMI1726
  • Industry : Pharmaceutical
  • Pages : 177
  • Formats :

Chronic myeloid leukemia (CML) is a type of cancer that starts in certain blood-forming cells of the bone marrow. It most commonly occurs in the adults and very rarely it occurs in children. Chronic myeloid leukemia usually begins after age 60. CML is develop slowly and treated with targeted cancer drugs such as tyrosine kinase inhibitors, chemotherapy or a bone marrow transplant. Recent advances in cancer treatments has drastically improved the survival rate for this type of leukemia.

The global chronic myeloid leukemia treatment market is estimated to be valued at US$ 7,216.3 million in 2021, and is expected to exhibit a CAGR of 6.0% during the forecast period (2021-2028).

Figure 1. Global Chronic Myeloid Leukemia Treatment Market in Terms of Value (US$ million), By Region, 2021

Chronic Myeloid Leukemia Treatment  | Coherent Market Insights

Increase in focus on research and development activities by key players is estimated to drive the global chronic myeloid leukemia treatment market growth during the forecast period.

Several market players and research institutes are involved in research and development activities related to chronic myeloid leukemia treatment, which is expected to fuel the growth of the global chronic myeloid leukemia treatment market in the near future. For instance, in December 2020, the U.S. Food and Administration approved supplemental new drug application for ICLUSIG (ponatinib) for adult patients with chronic myeloid leukemia (CML).

CMI table icon

Chronic Myeloid Leukemia Treatment Market Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2021: US$ 7,216.3 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2021 to 2028
Forecast Period 2021 to 2028 CAGR: 6.0% 2028 Value Projection: US$ 10,864.9 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Drug Type: Tyrosine Kinase Inhibitors (Imatinib (Gleevec), Dasatinib (Sprycel), Nilotinib (Tasigna), Bosutinib (Bosulif), Ponatinib (Iclusig), Asciminib (Scemblix), Others), Antimetabolites, Others)
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:

Teva Pharmaceutical Industries Ltd, F. Hoffmann-La Roche Ltd., Novartis AG, Bristol-Myers Squibb Company, Pfizer Inc., Takeda Pharmaceutical Company Limited, Innovent Biologics, Inc., Viatris Inc. (Mylan N.V.), Lupin, IL-YANG PHARM CO. LTD., Million Health Pharmaceuticals, and Celon Labs

Growth Drivers:
  • Increase in focus on research and development activities by key players
  • Increasing awareness programs regarding chronic myeloid leukemia
Restraints & Challenges:
  • High cost of chronic myeloid leukemia treatment drugs

Figure 2. Global Chronic Myeloid Leukemia Treatment Market Share (%), By Drug Type, 2021

Chronic Myeloid Leukemia Treatment  | Coherent Market Insights

Increasing awareness programs regarding chronic myeloid leukemia is anticipated to propel the global chronic myeloid leukemia treatment market growth over the forecast period.

The demand for drugs of chronic myeloid leukemia and its associated disorders such as blood cancers is rapidly increasing. The market players and non-profit organizations in various countries are implementing various initiatives and organizing awareness programs in order to increase the production of medications for chronic myeloid leukemia, which is expected to create lucrative opportunities for the chronic myeloid leukemia medication manufacturers and drive the market growth in the near future. For instance, on September 22, every year, the chronic myeloid leukemia (CML) Foundation Network conducts the World CML Day global awareness campaign.

Global Chronic Myeloid Leukemia Treatment Market – Impact of Coronavirus (COVID-19) Pandemic

The coronavirus (COVID-19) pandemic was first reported on December 31, 2019 in Wuhan, China. The World Health Organization (WHO) declared the COVID-19 a pandemic on March 11, 2020. The negative impact is mostly due to the delay in clinical trial study and product approval. Moreover, disturbance in supply chain due to COVID-19 is expected to hinder the growth of market.

Global Chronic Myeloid Leukemia Treatment Market: Restraints

Cost is a major factors that influences the selection of treatment. Thus, the high cost of chronic myeloid leukemia treatment drugs is expected to hamper the growth global chronic myeloid treatment market. Furthermore, in an article published by American Society of Clinical Oncology Journal in August 2020, mean annualized costs for CML was US$ 82,054, more than those for hematologic malignancies (HEM) US$ 74,993 in the U.S.

Key Players

Major players operating in the global chronic myeloid leukemia treatment market include Teva Pharmaceutical Industries Ltd, F. Hoffmann-La Roche Ltd., Novartis AG, Bristol-Myers Squibb Company, Pfizer Inc., Takeda Pharmaceutical Company Limited, Innovent Biologics, Inc., Viatris Inc. (Mylan N.V.), Lupin, IL-YANG PHARM CO. LTD., Million Health Pharmaceuticals, and Celon Labs.

Chronic myeloid leukemia (CML) is a cancer that initiates in the blood-forming cells of the bone marrow and enters the blood. It increases the number of white blood cells in the blood. Chronic myeloid leukemia is also known as chronic myelogenous leukemia. Chronic myeloid leukemia (CML) occurs mostly in adults, and rarely in children. Chronic myeloid leukemia (CML) is detected after the blood test is performed.

Chronic myeloid leukemia symptoms includes:

  • Bone pain
  • Easy bleeding
  • Fever
  • Weight loss
  • Excessive sweating during sleep

Market Dynamics

Increasing number of drug launches by market key players is expected to drive the growth of global chronic myeloid leukemia treatment market during the forecast period. For instance, in September 2017, Mylan N.V., a pharmaceutical company, announced the launch of Imatinib Mesylate tablets, 100 mg and 400 mg, a generic version of Novartis's Gleevec Tablets. Moreover, Mesylate tablets are approved by US Food and Drug Administration for the treatment of acute lymphoblastic leukemia, chronic eosinophilic leukemia or hypereosinophilic syndrome, chronic myelogenous leukemia, and others.

Increasing number of inorganic growth strategies such as strategic collaboration by market key players is expected to drive the growth of global chronic myeloid leukemia treatment market. For instance, in July 2021, Innovent Biologics, Inc., a biopharmaceutical company, announced strategic collaboration with Ascentage Pharma, a biopharmaceutical company. Moreover, this collaboration includes the joint clinical development and commercialization of HQP1351 (olverembatinib), a third-generation BCR-ABL inhibitor in China. Olverembatinib is indicated for the treatment of adult patients with tyrosine kinase inhibitor (TKI)-resistant chronic phase chronic myeloid leukemia (CML-CP) or accelerated-phase CML (CML-AP).

Key features of the study:

  • This report provides an in-depth analysis of global chronic myeloid leukemia treatment market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2021-2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in the global chronic myeloid leukemia treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans.
  • Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd., Novartis AG, Bristol-Myers Squibb Company, Pfizer, Inc., Takeda Pharmaceutical Company Limited, Innovent Biologics, Inc., Viatris Inc. (Mylan N.V.), Lupin, IL-YANG PHARM CO. LTD., Million Health Pharmaceuticals, and Celon Labs
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
  • The global chronic myeloid leukemia treatment market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global chronic myeloid leukemia treatment market

Detailed Segmentation:

  • Global Chronic Myeloid Leukemia Treatment Market, By Drug Type:
    • Tyrosine Kinase Inhibitors
      • Imatinib (Gleevac)
      • Dasatinib (Sprycel)
      • Nilotinib (Tasigna)
      • Bosutinib (Bosulif)
      • Ponatinib (Iclusig)
      • Asciminib (Scemblix)
      • Others
    • Antimetabolites
    • Others
  • Global Chronic Myeloid Leukemia Treatment Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Chronic Myeloid Leukemia Treatment Market, By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country:
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Teva Pharmaceutical Industries Ltd.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Hoffmann-La Roche Ltd.
    • Novartis AG
    • Bristol-Myers Squibb Company
    • Pfizer, Inc.
    • Takeda Pharmaceutical Company Limited
    • Innovent Biologics, Inc.
    • Viatris Inc. (Mylan N.V.)
    • Lupin
    • IL-YANG PHARM CO. LTD.
    • Million Health Pharmaceuticals
    • Celon Labs

“*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

The global chronic myeloid leukemia treatment market is estimated to be valued at US$ 7,216.3 million in 2021, and is expected to exhibit a CAGR of 6.0% between 2021 and 2028.
Factors such as increase in focus on research and development activities by key players is projected to boost the market growth over the forecast period.
The tyrosine kinase inhibitors segment is expected to hold a major market share of the market in 2021.
The major factor hampering the market growth include high cost of chronic myeloid leukemia treatment drugs.
Major players operating in the market include Teva Pharmaceutical Industries Ltd, F. Hoffmann-La Roche Ltd., Novartis AG, Bristol-Myers Squibb Company, Pfizer Inc., Takeda Pharmaceutical Company Limited, Innovent Biologics, Inc., Viatris Inc. (Mylan N.V.), Lupin, IL-YANG PHARM CO. LTD., Million Health Pharmaceuticals, and Celon Labs.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo